
|Videos|August 13, 2021
Aurion Biotech: Treating endothelial disease with one donor
Author(s)David Hutton, Alex Delaney-Gesing
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Advertisement
Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sharper vision starts here
2
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION
3
iOpeners: Zubair Ansari, MD, shares his global health journey with Nicole Bajic, MD
4
Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy
5